The diagnostic role of PTEN and ARID1A in serous effusions
The aim of this study was to analyze the diagnostic role of PTEN and ARID1A in effusion cytology. Effusions (n = 279), consisting of 226 carcinomas (70 ovarian, 64 breast, 36 lung, and 15 uterine corpus carcinomas; 41 carcinomas of other origin) and 53 malignant mesotheliomas, were analyzed for PTEN and ARID1A expression using immunohistochemistry. PTEN was preserved in 166 (59%) tumors, partially lost in 38 (14%), and absent in 75 (27%), with lower expression in malignant mesotheliomas compared to carcinomas, though not significantly (p = 0.084). ARID1A was preserved in 243 (88%) tumors, partially lost in 18 (6%), and absent in 18 (6%). The majority of tumors with absent ARID1A were ovarian carcinomas, predominantly of clear cell or low-grade serous type. Reactive mesothelial cells in carcinoma specimens were uniformly positive for both proteins. ARID1A mutation analysis showed no mutations in eight analyzed specimens negative by immunohistochemistry. Loss of PTEN and ARID1A expression is highly specific for malignancy in effusion pathology. Loss of PTEN is not informative of organ of origin, whereas absence of ARID1A should raise suspicion of an ovarian primary.
KeywordsPTEN ARID1A Effusions Immunohistochemistry Diagnosis
Compliance with ethical standards
The study was approved by the Regional Committee for Medical Research Ethics in Norway. Permission from the local ethics committee and patient consent were obtained at all locations according to national guidelines.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Davidson B, Firat P, Michael CW (eds) (2011) Serous effusions. Springer, London, UKGoogle Scholar
- 3.Hodges C, Kirkland JG, Crabtree GR (2016) The many roles of BAF (mSWI/SNF) and PBAF complexes in cancer. Cold Spring Harb Perspect Med 6(8). https://doi.org/10.1101/cshperspect.a026930
- 7.Maiques O, Santacana M, Valls J, Pallares J, Mirantes C, Gatius S, da García D, Amant F, Pedersen HC, Dolcet X, Matias-Guiu X (2014) Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues. Hum Pathol 45(3):522–532. https://doi.org/10.1016/j.humpath.2013.10.018 CrossRefPubMedGoogle Scholar
- 8.Djordjevic B, Hennessy BT, Li J, Barkoh BA, Luthra R, Mills GB, Broaddus RR (2012) Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol 25(5):699–708. https://doi.org/10.1038/modpathol.2011.208 CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Köbel M, Bak J, Bertelsen BI, Carpen O, Grove A, Hansen ES, Levin Jakobsen AM, Lidang M, Måsbäck A, Tolf A, Gilks CB, Carlson JW (2014) Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology 64(7):1004–1013. https://doi.org/10.1111/his.12349 CrossRefPubMedGoogle Scholar
- 11.Köbel M, Kalloger SE, Lee S, Ovarian Tumor Tissue Analysis consortium et al (2013) Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomark Prev 22(10):1677–1686. https://doi.org/10.1158/1055-9965.EPI-13-0391 CrossRefGoogle Scholar
- 15.Kawai T, Tominaga S, Hiroi S, Ogata S, Nakanishi K, Kawahara K, Sonobe H, Hiroshima K (2016) Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses. J Clin Pathol 69(8):706–712. https://doi.org/10.1136/jclinpath-2015-203211 CrossRefPubMedGoogle Scholar
- 18.Andrici J, Jung J, Sheen A, D’Urso L, Sioson L, Pickett J, Parkhill TR, Verdonk B, Wardell KL, Singh A, Clarkson A, Watson N, Toon CW, Gill AJ (2016) Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma. Hum Pathol 51:9–15. https://doi.org/10.1016/j.humpath.2015.12.012 CrossRefPubMedGoogle Scholar
- 19.Facchetti F, Lonardi S, Gentili F, Bercich L, Falchetti M, Tardanico R, Baronchelli C, Lucini L, Santin A, Murer B (2007) Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch 451(3):669–680. https://doi.org/10.1007/s00428-007-0448-x CrossRefPubMedGoogle Scholar
- 28.Williamson CT, Miller R, Pemberton HN, Jones SE, Campbell J, Konde A, Badham N, Rafiq R, Brough R, Gulati A, Ryan CJ, Francis J, Vermulen PB, Reynolds AR, Reaper PM, Pollard JR, Ashworth A, Lord CJ (2016) ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat Commun 7:13837. https://doi.org/10.1038/ncomms13837 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Miller RE, Brough R, Bajrami I, Williamson CT, McDade S, Campbell J, Kigozi A, Rafiq R, Pemberton H, Natrajan R, Joel J, Astley H, Mahoney C, Moore JD, Torrance C, Gordan JD, Webber JT, Levin RS, Shokat KM, Bandyopadhyay S, Lord CJ, Ashworth A (2016) Synthetic lethal targeting of ARID1A-mutant ovarian clear cell tumors with dasatinib. Mol Cancer Ther 15(7):1472–1484. https://doi.org/10.1158/1535-7163.MCT-15-0554 CrossRefPubMedGoogle Scholar
- 31.Berns K, Sonnenblick A, Gennissen A, Brohee S, Hijmans EM, Evers B, Fumagalli D, Desmedt C, Loibl S, Denkert C, Neven P, Guo W, Zhang F, Knijnenburg TA, Bosse T, van der Heijden MS, Hindriksen S, Nijkamp W, Wessels LFA, Joensuu H, Mills GB, Beijersbergen RL, Sotiriou C, Bernards R (2016) Loss of ARID1A activates ANXA1, which serves as a predictive biomarker for trastuzumab resistance. Clin Cancer Res 22(21):5238–5248. https://doi.org/10.1158/1078-0432.CCR-15-2996 CrossRefPubMedGoogle Scholar
- 32.Voss MH, Molina AM, Chen YB et al (2017) Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non-clear cell renal cell carcinoma. Clin Oncol 2016 Sep 6. Pii: JCO679084 [Epub ahead of print]Google Scholar
- 33.Cowell JK, Qin H, Hu T, Wu Q, Bhole A, Ren M (2017) Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas. Int J Cancer 141(9):1822–1829. https://doi.org/10.1002/ijc.30848 CrossRefPubMedGoogle Scholar
- 34.Koo DH, Lee HJ, Ahn JH, Yoon DH, Kim SB, Gong G, Son BH, Ahn SH, Jung KH (2015) Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer. Tumour Biol 36(8):5865–5871. https://doi.org/10.1007/s13277-015-3258-9 CrossRefPubMedGoogle Scholar
- 35.Loibl S, Darb-Esfahani S, Huober J, Klimowicz A, Furlanetto J, Lederer B, Hartmann A, Eidtmann H, Pfitzner B, Fasching PA, Tiemann K, Jackisch C, Mehta K, von Minckwitz G, Untch M, Denkert C (2016) Integrated analysis of PTEN and p4EBP1 protein expression as predictors for pCR in HER2-positive breast cancer. Clin Cancer Res 22(11):2675–2683. https://doi.org/10.1158/1078-0432.CCR-15-0965 CrossRefPubMedGoogle Scholar
- 37.George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter SL, Hammerman P, Freeman GJ, Wu CJ, Ott PA, Wong KK, van Allen EM (2017) Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine Leiomyosarcoma. Immunity 46(2):197–204. https://doi.org/10.1016/j.immuni.2017.02.001 CrossRefPubMedPubMedCentralGoogle Scholar